Latest News - Ivantis

Saturday, November 11, 2017 | Clinical Trials, Glaucoma, Ivantis

Ivantis FDA Clinical Trial of the Hydrus Microstent for Minimally Invasive Glaucoma Surgery Meets Endpoints, Exceeds Outcomes of Past MIGS Trials

Ivantis announced that the HORIZON pivotal study has met both the 2-year primary and secondary pre-established endpoints. Outcomes exceed those of any MIGS pivotal trial to date. Ivantis previously an…

Read the full story

Wednesday, November 01, 2017 | Glaucoma, Ivantis

Ivantis Completes Premarket Approval Submission for the Hydrus Microstent for Minimally Invasive Glaucoma Surgery

Ivantis, developer of thel Hydrus Microstent, announced that it has submitted its final premarket approval (PMA) module to the FDA for market approval. The HORIZON pivotal trial is a 556-patient, pros…

Read the full story

Monday, January 09, 2017 | Earnings & Financials, Ivantis

Ivantis Raises $25 Million Series C to Fund Future US Commercialization of the Hydrus Microstent for Minimally Invasive Glaucoma Surgery

Ivantis announced that it closed a $25 million Series C financing to support US commercialization of the Hydrus Microstent upon its anticipated 2018 FDA approval. The round was led by new investor RA …

Read the full story

Friday, April 17, 2015 | Clinical Trials, Ivantis

Ivantis Completes Enrollment in HYDRUS IV Glaucoma Study of the Hydrus Microstent

Ivantis announced the completion of subject enrollment in its HYDRUS IV pivotal trial. The study is being conducted at 36 centers worldwide and includes more than 550 subjects. It is the largest rando…

Read the full story